P3 Health Partners (PIII) Q2 2026: Adjusted EBITDA Surges to $54M on Contractual Restructuring and Operational Discipline
P3 Health Partners demonstrated significant financial and operational progress in Q2 2026, driven by deliberate contract rationalization and enhanced clinical execution. The company’s strategic network curation and point of care technology adoption underpin improving medical cost trends and quality metrics. Raised full-year guidance reflects confidence in durable earnings growth and disciplined expansion.
Summary
- Contractual and Operational Restructuring Embedded: Structural changes across contracts and network are compounding into improved profitability.
- Clinical Execution Drives Cost and Quality: Expanded point of care tools and utilization management advance medical cost trend and quality performance.
- Disciplined Growth Approach: Nebraska expansion progresses deliberately with full risk transition planned for 2028.
Business Overview
P3 Health Partners is a physician-led population health management company operating primarily in the Medicare Advantage (MA) space. The company generates revenue predominantly through capitated contracts, receiving fixed payments per member per month (PMPM) to manage healthcare services for enrolled populations. Its major business segments include at-risk membership under capitation arrangements and management services for non-risk lives, with a network of over 2,100 affiliated primary care providers across multiple states.
Performance Analysis
In Q2 2026, P3 reported total revenue of $386 million, up 9% year-over-year despite a 10% decline in at-risk membership to approximately 105,000 members. This revenue growth was primarily driven by a 15% increase in per-member capitated revenue, reflecting improved network economics, rate progression, and enhanced burden of illness capture. The company achieved an adjusted EBITDA of $54.4 million, a dramatic turnaround from a loss of $17.1 million in the prior year quarter. Notably, $41 million of this adjusted EBITDA was attributable to favorable payer settlements impacting medical claims expense but not revenue, highlighting strong payer relationships and contract resolution.
Underlying operations excluding settlements generated approximately $9 million of adjusted EBITDA, marking sustained core profitability and quarter-over-quarter improvement. Medical margin reached $97.8 million or $311 PMPM, with adjusted medical loss ratio at 85.6% after excluding settlements. The company’s medical cost trend was 1.8% below the 2025 baseline, significantly outperforming industry peers with typical trends of 5% to 7%. Adjusted operating expenses remained disciplined at $32 million, supporting frontline clinical capabilities and infrastructure investments in new markets like Nebraska.
- Revenue Expansion Despite Membership Rationalization: Contractual rate progression and burden of illness documentation drove revenue growth despite a smaller at-risk base.
- Medical Cost Trend Outperformance: A 1.8% reduction relative to prior year baseline signals effective clinical and utilization management.
- Core Profitability Emerging: Underlying adjusted EBITDA excluding settlements is positive and improving, indicating operational strength beyond one-time items.
These results reflect the cumulative impact of strategic contract restructuring, network concentration on high-performing relationships, and operational discipline in clinical and administrative functions.
Executive Commentary
"Q2 represents a continuation of the positive momentum we have built over the last two years and reflects sustained execution against the plan we shared with you at the outset of my tenure... Our results reflect the structural improvements now embedded across our contracts, our network, and our operating model... We remain focused on medical cost improvement, quality and burden of illness performance, disciplined growth, and continued operational improvements through people, process, and technology."
Aric Coffman, Chief Executive Officer
"Q2 was another strong quarter. We delivered $54 million of adjusted EBITDA, including approximately $9 million of underlying adjusted EBITDA, excluding favorable contractual settlements and prior year development... The core business itself is now generating positive adjusted EBITDA... We are raising our full year 2026 adjusted EBITDA outlook to a range of $80 million to $110 million, with a midpoint of $95 million."
Leif, Chief Financial Officer
Strategic Positioning
1. Contractual Rationalization and Network Concentration
P3 has deliberately exited underperforming arrangements, reducing at-risk membership by 10% year-over-year to focus on economically accretive contracts. Enhanced payer partnerships include redesigned risk sharing and funding mechanisms, which improve alignment and accountability. The $41 million payer settlements recognized in Q2 underscore strengthened relationships and trust with payers, while improved contract economics support sustainable margins.
2. Clinical Execution and Point of Care Technology
The company’s Care Enablement Model emphasizes proactive clinical engagement, utilization management, and payment integrity. The deployment of AI-enhanced point of care tools reached over 65,000 lives, with providers addressing nearly 90% of care gaps during visits. This technology adoption reduces administrative burden and improves diagnostic accuracy, directly contributing to medical cost trend outperformance and quality measure progress towards four-star ratings on HEDIS and medication adherence.
3. Disciplined Geographic Expansion
P3’s measured entry into Nebraska exemplifies its cautious approach to growth, focusing first on service arrangements in 2027 before assuming full risk in 2028. This glide path enables infrastructure build-out and performance validation, mitigating downside risk. The company continues to explore growth opportunities within existing markets and potential new geographies, emphasizing operational readiness and risk management.
4. Operational Discipline and Cost Management
Adjusted operating expenses held steady at $32 million, reflecting disciplined spending focused on frontline clinical capabilities and necessary infrastructure. Investments in professional fees and technology support ongoing improvements in quoting, documentation, and care management. The company balances growth initiatives with cost control to protect margins and cash flow.
5. Quality as a Differentiator
Quality outcomes remain a core strategic lever, with P3 tracking ahead of its internal glide path towards four-star Medicare Advantage ratings. Improved quality performance not only benefits patients but strengthens payer relationships and contract economics. The company’s focus on alternative submissions and quality gap closures is driving meaningful increases in members impacted by quality initiatives.
Key Considerations
P3’s Q2 results reflect the interplay of structural contract changes, clinical execution, and operational discipline driving improved financial outcomes and positioning for sustainable growth.
- Settlements Impact Profitability: Favorable payer settlements materially boosted adjusted EBITDA but are non-recurring; core profitability is improving but remains modest.
- Medical Cost Trend Leadership: A 1.8% reduction versus 2025 baseline positions P3 well against peers facing higher inflationary pressures.
- Technology Adoption Accelerates: Point of care tool utilization at half of office visits demonstrates strong provider engagement and potential for further clinical gains.
- Membership Rationalization Risks: Exiting lower-performing contracts reduces scale but enhances economic quality; future growth hinges on disciplined expansion execution.
- Capital and Liquidity Management: Cash and equivalents of $21 million support ongoing investment but require monitoring given seasonality and expansion plans.
Risks
P3 faces risks from potential shifts in payer benefit designs and market exits which could affect membership levels. The company’s reliance on favorable payer settlements to boost near-term profitability introduces earnings volatility. Additionally, execution risk remains around technology adoption scale and geographic expansion timing. Regulatory and competitive pressures in Medicare Advantage markets also present ongoing challenges.
Forward Outlook
For Q3 2026, P3 anticipates continued underlying adjusted EBITDA growth, with management expecting approximately $15 million in additional EBITDA in the back half of 2026, factoring seasonal medical expense pressures offset by programmatic interventions. Full-year adjusted EBITDA guidance was raised to a range of $80 million to $110 million, reflecting confidence in contract economics and operational execution. At-risk membership is projected between 102,000 and 106,000 members for the full year, consistent with the company’s focus on high-quality relationships.
Takeaways
P3 Health Partners’ Q2 results mark a pivotal point in the company’s multi-year transformation, with embedded structural and operational improvements translating into positive core profitability and raised guidance.
- Embedded Contract and Network Discipline: The deliberate portfolio pruning and contract redesigns are yielding improved economics and stronger payer alignment, foundational for durable earnings.
- Clinical and Technology Execution Drive Differentiation: Advanced point of care tools and utilization management programs are key drivers of medical cost trend outperformance and quality progress.
- Measured Growth Balances Risk and Opportunity: The cautious expansion approach, exemplified by Nebraska, mitigates downside risk while positioning for future at-risk membership growth.
Conclusion
P3 Health Partners is transitioning into a phase of sustained operational and financial strength, underpinned by strategic contract rationalization, clinical innovation, and disciplined growth. While risks remain around membership scale and payer dynamics, the company’s raised guidance and improving core profitability signal a positive trajectory for 2026 and beyond.
Industry Read-Through
P3’s demonstrated ability to reduce medical cost trends below industry averages highlights the growing importance of integrated clinical technology and utilization management in Medicare Advantage. The company’s experience with contract restructuring and payer settlements underscores the evolving nature of risk-sharing arrangements in population health management. Other players in the sector should note the value of deliberate network curation and technology-enabled care coordination as levers to improve margins and quality. Additionally, P3’s cautious geographic expansion approach offers a model for balancing growth ambitions with operational readiness in a competitive and regulated environment.